DOCSLIB.ORG

Development of a New Platform Technology for Plant Cytochrome P450 Fusions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of a New Platform Technology for Plant Cytochrome P450 Fusions Development of a new platform technology for plant Cytochrome P450 fusions Julia Schückel PhD Thesis University of York Department of Biology January 2012 ABSTRACT Abstract To date more than 15000 Cytochromes P450 have been identified and named so far, with one third belonging to the plant kingdom. This is a key biochemical resource, providing a wealth of biocatalysts covering a diverse range of chemistries. Characterisation, however, has been greatly hindered by the poor solubility of many P450s, a result of the membrane anchoring region common to all plant P450s. Fusions of plant P450 heme domains to an appropriate reductase without the hydrophobic membrane anchor could provide the basis for developing robust, soluble plant enzyme systems for substrate screens to discover novel activities that are also of benefit to industry. In this project, the two predominantly expressed Arabidopsis reductases ATR1 and ATR2 have been cloned, without the membrane anchor, and expressed in Escherichia coli. These two truncated enzymes have been purified and assessed for activity with ATR2 found to be more active than ATR1. ATR2 was chosen for engineering into a novel plant P450 reductase vector platform for high throughput applications, whereby the P450s can be easily and quickly swapped using ligation independent cloning techniques. Four different plant P450s (CYP93C1, CYP73A5, CYP82E4 and CYP81D8) were selected to validate this technology, and activity for the fusions of CYP93C1 (Isoflavone synthase I from Glycine max) and CYP73A5 (cinnamate-4-hydroxylase from Arabidopsis) with ATR2 have been shown. The presence of CYP73A5 fused to ATR2 was verified through purification and further studies showed that it has to be membrane associated for activity. Additionally, CYP93C1 and CYP73A5 were also fused with the bacterial RhF reductase from Rhodococcus sp. and expressed in E. coli and compared to the plant P450 – plant reductase fusion protein. These novel plant-bacterial fusion P450 systems are the first example of active plant P450s fused to a reductase from a bacterium. This platform technology will provide the possibility for characterisation studies of eukaryotic P450s with unknown function and the discovery of new activities. 2 TABLE OF CONTANTS Abstract .................................................................................... 2 List of Tables ........................................................................... 8 List of Figures .......................................................................... 9 Acknowledgements ............................................................... 14 Author’s Declaration ............................................................ 15 1 Introduction ...................................................................... 16 1.1 Biotransformations in Industry ............................................... 16 1.2 Cytochromes P450 .................................................................... 17 1.2.1 History and Nomenclature of Cytochromes P450 ....................... 17 1.2.2 Structure and Function of Cytochromes P450 ............................ 22 1.2.3 Reaction Mechanism ...................................................................... 25 1.2.4 Cytochromes P450 reactions ......................................................... 27 1.2.5 Interactions between Cytochromes P450 and reductases ........... 28 1.2.6 Cytochrome P450 Fusion Systems ................................................ 29 1.3 Applications of Cytochromes P450 in biocatalysis ................ 33 1.3.1 Hydroxylation ................................................................................. 33 1.3.2 Oxidation ......................................................................................... 35 1.4 Plant Cytochromes P450 .......................................................... 37 1.4.1 Cytochromes P450s in Arabidopsis thaliana ............................... 37 1.4.2 Fusions of plant Cytochromes P450 .............................................. 43 1.5 Recombinant Expression Systems ........................................... 47 1.5.1 Expression of P450s in Escherichia coli........................................ 48 1.5.2 Expression in Yeast ........................................................................ 48 1.6 Aim of the project ..................................................................... 50 2 Materials and Methods .................................................... 51 2.1 Reagents and consumables ....................................................... 51 2.2 Media, strains and plasmids .................................................... 52 2.2.1 Bacterial media ............................................................................... 52 2.2.2 Bacterial strains .............................................................................. 53 2.2.3 Plasmids for gene cloning and enzyme expression ...................... 55 2.3 Preparation of chemically competent Escherichia coli cells . 58 2.4 Plant media, growth conditions and strains ........................... 59 2.5 Plasmid DNA preparation ........................................................ 60 2.6 Purification of DNA fragments ................................................ 60 2.7 Detection of the mRNA transcript .......................................... 60 2.7.1 RNA extraction from Escherichia coli .......................................... 60 3 TABLE OF CONTANTS 2.7.2 RNA extraction from plant tissue ................................................. 61 2.7.3 Reverse transcription from plant mRNA to cDNA ..................... 62 2.8 Traditional cloning method ...................................................... 62 2.8.1 Designing primers for truncated P450 and reductase genes ...... 62 2.8.2 Polymerase chain reaction (PCR) ................................................. 62 2.8.3 Preparation of PCR products for cloning .................................... 63 2.8.4 Transformation of plasmid DNA into chemically competent Escherichia coli cells ....................................................................... 63 2.8.5 Screening transformants for recombinant genes by PCR .......... 64 2.8.6 Restriction endonuclease digest of DNA ....................................... 64 2.8.7 Dephosphorylation of DNA 5’ end of the vector .......................... 64 2.8.8 DNA ligation reaction..................................................................... 65 2.8.9 DNA sequencing and analysis........................................................ 65 2.9 Ligation independent cloning method .................................... 66 2.10 Protein expression and purification .................................... 67 2.10.1 Expression in Escherichia coli ....................................................... 67 2.10.2 Solubilisation buffers...................................................................... 68 2.10.3 Cell lysis by sonication ................................................................... 70 2.10.4 Protein purification in a batch process ......................................... 71 2.10.5 Protein purification in a continuous process ............................... 71 2.11 Agarose gel electrophoesis.................................................... 72 2.12 Protein detection ................................................................... 72 2.13 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) ......................................................... 72 2.13.1 SDS PAGE with the Bio-Rad system ............................................ 72 2.13.2 SDS PAGE with the RunBlue system from Expedeon ................ 73 2.14 Western blot analysis ............................................................ 73 2.14.1 Protein detection with anti-poly Histidine peroxidase conjugate73 2.14.2 Protein detection with alkaline phosphatase conjugate .............. 74 2.15 Protein characterisation ....................................................... 75 2.15.1 Characterisation of the P450 reductases ...................................... 75 2.15.1.1 Spectrophotometric characterisation ........................................... 75 2.15.1.2 Activity assay with cytochrome c ................................................ 75 2.15.1.3 Temperature and pH optima of ATR1tr and ATR2tr .................. 76 2.15.1.4 Stability test of ATR2tr in different buffers ................................ 77 2.15.1.5 Kinetic studies of the reductases .................................................. 77 2.15.2 Protein identification by MALDI-MS analysis ............................ 78 2.15.3 P450 enzyme activity assays .......................................................... 78 2.15.3.1 Activity assay for CYP71D15 with limonene ............................. 78 4 TABLE OF CONTANTS 2.15.3.2 Activity assay for CYP81D8 and CYP81D11 with methyl-tolyl- suphide ......................................................................................... 79 2.15.3.3 Isoflavone synthase activity assay ............................................... 80 2.15.3.4 Cinnamate-4-hydroxylase (CYP73A5) activity assay ................. 81 2.15.3.5 Activity assay for CYP82E4 ........................................................ 82 2.15.3.6 Activity assay for CYP81D8 with TNT and aminodinitrotoluenes83 2.15.3.7 Activity assay for CYP81D8 with 7-ethoxycoumarin ................. 84 3 Chapter: Expression of Cytochromes P450 ................... 86 3.1 Introduction ..............................................................................
Load more

Recommended publications
  • Electron Transfer Partners of Cytochrome P450
    4 Electron Transfer Partners of Cytochrome P450 Mark J.l. Paine, Nigel S. Scrutton, Andrew W. Munro, Aldo Gutierrez, Gordon C.K. Roberts, and C. Roland Wolf 1. Introduction Although P450 redox partners are usually expressed independently, "self-sufficient" P450 monooxygenase systems have also evolved through Cytochromes P450 contain a heme center the fusion of P450 and CPR genes. These fusion where the activation of molecular oxygen occurs, molecules are found in bacteria and fungi, the best- resulting in the insertion of a single atom of known example being P450 BM3, a fatty acid oxygen into an organic substrate with the con­ (0-2 hydroxylase from Bacillus megaterium, which comitant reduction of the other atom to water. The comprises a soluble P450 with a fiised carboxyl- monooxygenation reaction requires a coupled and terminal CPR module (recently reviewed by stepwise supply of electrons, which are derived Munro^). BM3 has the highest catalytic activity from NAD(P)H and supplied via a redox partner. known for a P450 monooxygenase^ and was for P450s are generally divided into two major classes many years the only naturally occurring ftised sys­ (Class I and Class II) according to the different tem known until the identification of a eukaryotic types of electron transfer systems they use. P450s membrane-bound equivalent fatty acid hydroxy­ in the Class I family include bacterial and mito­ lase, CYP505A1, from the phytopathogenic fungus chondrial P450s, which use a two-component Fusarium oxysporurrP. A number of novel P450 sys­ shuttle system consisting of an iron-sulfur protein tems are starting to emerge from the large numbers (ferredoxin) and ferredoxin reductase (Figure 4.1).
    [Show full text]
  • UC Berkeley UC Berkeley Electronic Theses and Dissertations
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Oriented Attachment of Cytochrome P450 2C9 to a Self-Assembled Monolayer on a Gold Electrode as a Biosensor Design Permalink https://escholarship.org/uc/item/1m67k8mm Author Schneider, Elizabeth Publication Date 2011 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Oriented Attachment of Cytochrome P450 2C9 to a Self-Assembled Monolayer on a Gold Electrode as a Biosensor Design by Elizabeth Ann Schneider A dissertation submitted in partial satisfaction of the requirements for the degree of Joint Doctor of Philosophy with the University of California, San Francisco in Bioengineering in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Douglas S. Clark, Chair Associate Professor Shuvo Roy Professor Liwei Lin Dr. Robert Kostecki Fall 2011 Abstract Oriented Attachment of Cytochrome P450 2C9 to a Self-Assembled Monolayer on a Gold Electrode as a Biosensor Design by Elizabeth Ann Schneider Doctor of Philosophy in Bioengineering University of California, Berkeley Professor Douglas S. Clark, Chair Cytochrome P450s (CYPs) are a family of enzymes implicated in the metabolism of drugs in the body. Consequently, P450 reactions are of high interest to the pharmaceutical industry, where lead compounds in drug development are screened as potential substrates of CYPs. The P450 reaction involves electron transfer to an iron heme via NADPH and the electron transfer partner enzyme P450 reductase (CPR). By immobilizing CYPs on an electrode however, NADPH and CPR are potentially no longer needed and the immobilized CYP can act as a biosensor by accepting electrons directly from the electrode.
    [Show full text]
  • 1 AMINO ACIDS Commonly, 21 L-Amino Acids Encoded by DNA Represent the Building Blocks of Animal, Plant, and Microbial Proteins
    1 AMINO ACIDS Commonly, 21 L-amino acids encoded by DNA represent the building blocks of animal, plant, and microbial proteins. The basic amino acids encountered in proteins are called proteinogenic amino acids 1.1). Biosynthesis of some of these amino acids proceeds by ribosomal processes only in microorganisms and plants and the ability to synthesize them is lacking in animals, including human beings. These amino acids have to be obtained in the diet (or produced by hydrolysis of body proteins) since they are required for normal good health and are referred to as essential amino acids. The essential amino acids are arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. The rest of encoded amino acids are referred to as non-essential amino acids (alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, serine, and tyrosine). Arginine and histidine are classified as essential, sometimes as semi-essential amino acids, as their amount synthesized in the body is not sufficient for normal growth of children. Although it is itself non-essential, cysteine (classified as conditionally essential amino acid) can partly replace methionine, which is an essential amino acid. Similarly, tyrosine can partly replace phenylalanine. 1.1 The glutamic acid group 1.1.1 Glutamic acid and glutamine Free ammonium ions are toxic to living cells and are rapidly incorporated into organic compounds. One of such transformations is the reaction of ammonia with 2-oxoglutaric acid from the citric acid cycle to produce L-glutamic acid. This reaction is known as reductive amination. Glutamic acid is accordingly the amino acid generated first as both constituent of proteins and a biosynthetic precursor.
    [Show full text]
  • Metabolic Engineering Yeast Cells for Medium‑Chained Biofuel Synthesis
    This document is downloaded from DR‑NTU (https://dr.ntu.edu.sg) Nanyang Technological University, Singapore. Metabolic engineering yeast cells for medium‑chained biofuel synthesis Li, Xiang 2015 Li, X. (2015). Metabolic engineering yeast cells for medium‑chained biofuel synthesis. Doctoral thesis, Nanyang Technological University, Singapore. https://hdl.handle.net/10356/62904 https://doi.org/10.32657/10356/62904 Downloaded on 02 Oct 2021 17:55:26 SGT METABOLIC ENGINEERING YEAST CELLS FOR MEDIUM METABOLIC ENGINEERING YEAST CELLS FOR MEDIUM-CHAINED BIOFUEL SYNTHESIS - CHAINED BIOFUEL SYNTHESIS LI XIANGLI 201 LI XIANG 5 SCHOOL OF CHEMICAL AND BIOMEDICAL ENGINEERING 2015 METABOLIC ENGINEERING YEAST CELLS FOR MEDIUM-CHAINED BIOFUEL SYNTHESIS LI XIANG LI XIANGLI School of Chemical and Biomedical Engineering A thesis submitted to the Nanyang Technological University in partial fulfillment of the requirement for the degree of Doctor of Philosophy 2015 Acknowledgements ACKNOWLEDGEMENTS Four years at Nanyang Technological University were unforgettable. NTU provided me a platform to pursue my degree and opportunity to get to know the most frontier areas and so many outstanding researchers who generously offered me sincere help. Herein, I would like to extend my deep appreciations to them. First and foremost, I would like to thank my supervisor, Prof. Chen Wei Ning William. He kindly provided me the opportunity to pursue my PhD, which has been a great honor. He has always been so kind and supportive and the family-like atmosphere in our research group really has made the four years enjoyable. His professional guidance, enlightening instructions and patient supervisions supported me in every stage in the process of generating this essay.
    [Show full text]
  • (10) Patent No.: US 8119385 B2
    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
    [Show full text]
  • ( 12 ) United States Patent
    US010208322B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,208 , 322 B2 Coelho et al. (45 ) Date of Patent: * Feb . 19, 2019 ( 54 ) IN VIVO AND IN VITRO OLEFIN ( 56 ) References Cited CYCLOPROPANATION CATALYZED BY HEME ENZYMES U . S . PATENT DOCUMENTS 3 , 965 ,204 A 6 / 1976 Lukas et al. (71 ) Applicant: California Institute of Technology , 4 , 243 ,819 A 1 / 1981 Henrick Pasadena , CA (US ) 5 ,296 , 595 A 3 / 1994 Doyle 5 , 703 , 246 A 12 / 1997 Aggarwal et al. 7 , 226 , 768 B2 6 / 2007 Farinas et al. ( 72 ) Inventors : Pedro S . Coelho , Los Angeles, CA 7 , 267 , 949 B2 9 / 2007 Richards et al . (US ) ; Eric M . Brustad , Durham , NC 7 ,625 ,642 B2 12 / 2009 Matsutani et al. (US ) ; Frances H . Arnold , La Canada , 7 ,662 , 969 B2 2 / 2010 Doyle et al. CA (US ) ; Zhan Wang , San Jose , CA 7 ,863 ,030 B2 1 / 2011 Arnold (US ) ; Jared C . Lewis , Chicago , IL 8 ,247 ,430 B2 8 / 2012 Yuan 8 , 993 , 262 B2 * 3 / 2015 Coelho . .. .. .. • * • C12P 7 /62 (US ) 435 / 119 9 ,399 , 762 B26 / 2016 Farwell et al . (73 ) Assignee : California Institute of Technology , 9 , 493 ,799 B2 * 11 /2016 Coelho .. C12P 7162 Pasadena , CA (US ) 2006 / 0030718 AL 2 / 2006 Zhang et al. 2006 / 0111347 A1 5 / 2006 Askew , Jr . et al. 2007 /0276013 AL 11 /2007 Ebbinghaus et al . ( * ) Notice : Subject to any disclaimer , the term of this 2009 /0238790 A2 9 /2009 Sommadosi et al. patent is extended or adjusted under 35 2010 / 0056806 A1 3 / 2010 Warren U .
    [Show full text]
  • Characterization of a Second Secologanin Synthase Isoform
    Dugé de Bernonville et al. BMC Genomics (2015) 16:619 DOI 10.1186/s12864-015-1678-y RESEARCH ARTICLE Open Access Characterization of a second secologanin synthase isoform producing both secologanin and secoxyloganin allows enhanced de novo assembly of a Catharanthus roseus transcriptome Thomas Dugé de Bernonville1†, Emilien Foureau1†, Claire Parage1†, Arnaud Lanoue1, Marc Clastre1, Monica Arias Londono1,2, Audrey Oudin1, Benjamin Houillé1, Nicolas Papon1, Sébastien Besseau1, Gaëlle Glévarec1, Lucia Atehortùa2, Nathalie Giglioli-Guivarc’h1, Benoit St-Pierre1, Vincenzo De Luca3, Sarah E. O’Connor4 and Vincent Courdavault1* Abstract Background: Transcriptome sequencing offers a great resource for the study of non-model plants such as Catharanthus roseus, which produces valuable monoterpenoid indole alkaloids (MIAs) via a complex biosynthetic pathway whose characterization is still undergoing. Transcriptome databases dedicated to this plant were recently developed by several consortia to uncover new biosynthetic genes. However, the identification of missing steps in MIA biosynthesis based on these large datasets may be limited by the erroneous assembly of close transcripts and isoforms, even with the multiple available transcriptomes. Results: Secologanin synthases (SLS) are P450 enzymes that catalyze an unusual ring-opening reaction of loganin in the biosynthesis of the MIA precursor secologanin. We report here the identification and characterization in C. roseus of a new isoform of SLS, SLS2, sharing 97 % nucleotide sequence identity with the previously characterized SLS1. We also discovered that both isoforms further oxidize secologanin into secoxyloganin. SLS2 had however a different expression profile, being the major isoform in aerial organs that constitute the main site of MIA accumulation. Unfortunately, we were unable to find a current C.
    [Show full text]
  • Engineering of Cytochrome P450s CYP109E1 and CYP109A2 from Bacillus Megaterium DSM319 for The
    Engineering of Cytochrome P450s CYP109E1 and CYP109A2 from Bacillus megaterium DSM319 for the production of vitamin D3 metabolites Kumulative Dissertation zur Erlangen des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät der Universität des Saarlandes von Ammar Abdulmughni Saarbrücken 2018 Tag des Kolloquiums : 14.08.2018 Dekan : Prof. Dr. Guido Kickelbick Berichterstatter : Prof. Dr. Rita Bernhardt Prof. Dr. Gert-Wieland Kohring Vorsitz : Prof. Dr. Uli Müller Akad. Mitarbeiter: Dr. Ing. Michael Kohlstedt Abstract Active vitamin D3 metabolites play an essential role in the maintenance of calcium and phosphorus homeostasis. The conventional chemical synthesis of this metabolite is time- consuming, environmentally unfriendly and often results in low yield. Therefore, the biotechnological production of active vitamin D3 metabolites is of great importance to the pharmaceutical industry. Hereby, cytochrome P450 enzymes have the potential to achieve this goal. The present work reports on the optimization of a biotechnological process in Bacillus megaterium MS941 for the production of vitamin D3 metabolites. On that account, two cytochrome P450 enzymes were used as biocataylsts, namely CYP109E1 and CYP109A2 from the Gram-positive bacterium Bacillus megaterium DSM319. Both enzymes were subjected for functional and structural characterization in order to optimize their activity and/or regio-selectivity towards vitamin D3. In terms of hydroxylation activity, it has been shown that the conversion of vitamin D3 with CYP109E1 results in the formation of several derivatives, while CYP109A2 shows clearly a higher regio-selectivity towards 25- hydroxylation. The elucidation of the crystal structure of both enzymes provides detailed insights into the geometry of these enzymes. By means of molecular docking, site-directed mutagenesis was successfully performed, resulting in the creation of mutants with higher regio-selectivity compared to the wild type, in particular when using CYP109E1.
    [Show full text]
  • Bifunctional CYP81AA Proteins Catalyse Identical Hydroxylations but Alternative Regioselective Phenol Couplings in Plant Xanthone Biosynthesis
    ARTICLE Received 27 Oct 2015 | Accepted 30 Mar 2016 | Published 5 May 2016 DOI: 10.1038/ncomms11472 OPEN Bifunctional CYP81AA proteins catalyse identical hydroxylations but alternative regioselective phenol couplings in plant xanthone biosynthesis Islam El-Awaad1,2,w, Marco Bocola3, Till Beuerle1,2, Benye Liu1,2 & Ludger Beerhues1,2 Xanthones are natural products present in plants and microorganisms. In plants, their biosynthesis starts with regioselective cyclization of 2,30,4,6-tetrahydroxybenzophenone to either 1,3,5- or 1,3,7-trihydroxyxanthones, catalysed by cytochrome P450 (CYP) enzymes. Here we isolate and express CYP81AA-coding sequences from Hypericum calycinum and H. perforatum in yeast. Microsomes catalyse two consecutive reactions, that is, 30-hydro- xylation of 2,4,6-trihydroxybenzophenone and C–O phenol coupling of the resulting 2,30, 4,6-tetrahydroxybenzophenone. Relative to the inserted 30-hydroxyl, the orthologues Hc/HpCYP81AA1 cyclize via the para position to form 1,3,7-trihydroxyxanthone, whereas the paralogue HpCYP81AA2 directs cyclization to the ortho position, yielding the isomeric 1,3,5- trihydroxyxanthone. Homology modelling and reciprocal mutagenesis reveal the impact of S375, L378 and A483 on controlling the regioselectivity of HpCYP81AA2, which is converted into HpCYP81AA1 by sextuple mutation. However, the reciprocal mutations in HpCYP81AA1 barely affect its regiospecificity. Product docking rationalizes the alternative C–O phenol coupling reactions. Our results help understand the machinery of bifunctional CYPs. 1 Institute of Pharmaceutical Biology, Technische Universita¨t Braunschweig, Mendelssohnstrae 1, Braunschweig 38106, Germany. 2 Center of Pharmaceutical Engineering (PVZ), Technische Universita¨t Braunschweig, Franz-Liszt-Strae 35A, Braunschweig 38106, Germany. 3 Institute of Biotechnology, RWTH Aachen University, Worringerweg 1, Aachen 52074, Germany.
    [Show full text]
  • Conformational Changes in Binding of Substrates with Human Cytochrome P450 Enzymes
    Book of oral abstracts 100 Conformational changes in binding of substrates with human cytochrome P450 enzymes F. Peter Guengerich, Clayton J. Wilkey, Michael J. Reddish, Sarah M. Glass, and Thanh T. N. Phan Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA Introduction. Extensive evidence now exists that P450 enzymes can exist in multiple conformations, at least in the substrate-bound forms (e.g., crystallography). This multiplicity can be the result of either an induced fit mechanism or conformational selection (selective substrate binding to one of two or more equilibrating P450 conformations). Aims. Kinetic approaches can be used to distinguish between induced fit and conformational selection models. The same energy is involved in reaching the final state, regardless of the kinetic path. Methods. Stopped-flow absorbance and fluorescence measurements were made with recombinant human P450 enzymes. Analysis utilized kinetic modeling software (KinTek Explorer®). Results. P450 17A1 binding to its steroid ligands (pregnenolone and progesterone and the 17-hydroxy derivatives) is dominated by a conformational selection process, as judged by (a) decreasing rates of substrate binding as a function of substrate concentration, (b) opposite patterns of the dependence of binding rates as a function of varying concentrations of (i) substrate and (ii) enzyme, and (c) modeling of the data in KinTek Explorer. The inhibitory drugs orteronel and abiraterone bind P450 17A1 in multi-step processes, apparently in different ways. The dye Nile Red is also a substrate for P450 17A1 and its sequential binding to the enzyme can be resolved in fluorescence and absorbance changes. P450s 2C8, 2D6, 2E1, and 4A11 have also been analyzed with regard to substrate binding and utilize primarily conformational selection models, as revealed by analysis of binding rates vs.
    [Show full text]
  • Progress in the Production of Medicinally Important Secondary
    Progress in the production of medicinally important secondary metabolites in recombinant microorganisms or plants-Progress in alkaloid biosynthesis Michael Wink, Holger Schäfer To cite this version: Michael Wink, Holger Schäfer. Progress in the production of medicinally important secondary metabo- lites in recombinant microorganisms or plants-Progress in alkaloid biosynthesis. Biotechnology Jour- nal, Wiley-VCH Verlag, 2009, 4 (12), pp.1684. 10.1002/biot.200900229. hal-00540529 HAL Id: hal-00540529 https://hal.archives-ouvertes.fr/hal-00540529 Submitted on 27 Nov 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biotechnology Journal Progress in the production of medicinally important secondary metabolites in recombinant microorganisms or plants-Progress in alkaloid biosynthesis For Peer Review Journal: Biotechnology Journal Manuscript ID: biot.200900229.R1 Wiley - Manuscript type: Review Date Submitted by the 28-Oct-2009 Author: Complete List of Authors: Wink, Michael; Heidelberg University, Institute for Pharmacy and Molecular Biotechnology
    [Show full text]
  • Optimization of the Bacterial Cytochrome P450 BM3 System for the Production of Human Drug Metabolites
    Int. J. Mol. Sci. 2012, 13, 15901-15924; doi:10.3390/ijms131215901 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Optimization of the Bacterial Cytochrome P450 BM3 System for the Production of Human Drug Metabolites Giovanna Di Nardo and Gianfranco Gilardi * Department of Life Sciences and Systems Biology, University of Torino, via Accademia Albertina 13, 10123 Torino, Italy; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-011-670-4593; Fax: +39-011-670-4643. Received: 27 September 2012; in revised form: 1 November 2012 / Accepted: 13 November 2012 / Published: 28 November 2012 Abstract: Drug metabolism in human liver is a process involving many different enzymes. Among them, a number of cytochromes P450 isoforms catalyze the oxidation of most of the drugs commercially available. Each P450 isoform acts on more than one drug, and one drug may be oxidized by more than one enzyme. As a result, multiple products may be obtained from the same drug, and as the metabolites can be biologically active and may cause adverse drug reactions (ADRs), the metabolic profile of a new drug has to be known before this can be commercialized. Therefore, the metabolites of a certain drug must be identified, synthesized and tested for toxicity. Their synthesis must be in sufficient quantities to be used for metabolic tests. This review focuses on the progresses done in the field of the optimization of a bacterial self-sufficient and efficient cytochrome P450, P450 BM3 from Bacillus megaterium, used for the production of metabolites of human enzymes.
    [Show full text]